Across TCGA pan-cancer cohorts, TMLHE Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMLHE data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMLHE Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMLHE expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and SKCM are the cancer types where TMLHE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.010	0.768	<.001	38	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.027	6	view →
SKCM	DFS	Median	II,III,IV	0.192	0.712	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TMLHE tumor-vs-normal RNA expression · all TMLHE data types